Clinical Trial Results:
An Interventional Efficacy And Safety, Phase 2/3, Double-Blind, 2-Arm Study To Investigate Orally Administered PF-07321332/Ritonavir Compared With Placebo In Nonhospitalised Symptomatic Adult Subjects With Covid-19 Who Are At Low Risk Of Progressing To Severe Illness
Summary
|
|
EudraCT number |
2021-002857-28 |
Trial protocol |
ES HU BG CZ SK |
Global end of trial date |
25 Jul 2022
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
11 Aug 2023
|
First version publication date |
11 Aug 2023
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
C4671002
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT05011513 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Pfizer Inc.
|
||
Sponsor organisation address |
235 E 42nd Street, New York, United States, NY 10017
|
||
Public contact |
Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
|
||
Scientific contact |
Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
09 Mar 2023
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
25 Jul 2022
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
An Interventional Efficacy And Safety, Phase 2/3, Double-Blind, 2-Arm Study To Investigate Orally Administered Pf-07321332/Ritonavir Compared With Placebo In Nonhospitalised Symptomatic Adult Subjects With Covid-19 Who Are At Low Risk Of Progressing To Severe Illness
|
||
Protection of trial subjects |
The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials subjects were followed.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
25 Aug 2021
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety, Efficacy | ||
Long term follow-up duration |
6 Months | ||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Argentina: 47
|
||
Country: Number of subjects enrolled |
Brazil: 32
|
||
Country: Number of subjects enrolled |
Bulgaria: 260
|
||
Country: Number of subjects enrolled |
Colombia: 13
|
||
Country: Number of subjects enrolled |
Czechia: 6
|
||
Country: Number of subjects enrolled |
Hungary: 19
|
||
Country: Number of subjects enrolled |
Japan: 13
|
||
Country: Number of subjects enrolled |
Korea, Democratic People's Republic of: 5
|
||
Country: Number of subjects enrolled |
Malaysia: 19
|
||
Country: Number of subjects enrolled |
Mexico: 113
|
||
Country: Number of subjects enrolled |
Poland: 11
|
||
Country: Number of subjects enrolled |
Puerto Rico: 6
|
||
Country: Number of subjects enrolled |
Romania: 1
|
||
Country: Number of subjects enrolled |
Slovakia: 25
|
||
Country: Number of subjects enrolled |
South Africa: 24
|
||
Country: Number of subjects enrolled |
Spain: 24
|
||
Country: Number of subjects enrolled |
Thailand: 94
|
||
Country: Number of subjects enrolled |
Turkey: 75
|
||
Country: Number of subjects enrolled |
Ukraine: 88
|
||
Country: Number of subjects enrolled |
United States: 413
|
||
Worldwide total number of subjects |
1288
|
||
EEA total number of subjects |
346
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
1223
|
||
From 65 to 84 years |
65
|
||
85 years and over |
0
|
|
||||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||||
Recruitment details |
Subjects who had confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as determined by reverse transcription polymerase chain reaction (RT-PCR) within 5 days prior to randomization were included in the study. | |||||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||||
Screening details |
A total of 1440 subjects signed informed consent form and were randomised. Out of which, 1288 subjects received study drug. | |||||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
|||||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | |||||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||||
Arm title
|
Nirmatrelvir 300 milligram (mg) + Ritonavir 100 mg | |||||||||||||||||||||||||||
Arm description |
Subjects were randomised to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5 | |||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||
Investigational medicinal product name |
Ritonavir
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
|||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||
Dosage and administration details |
Ritonavir 100 mg every 12 hours
|
|||||||||||||||||||||||||||
Investigational medicinal product name |
Nirmatrelvir
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
|||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||
Dosage and administration details |
Nirmatrelvir 300 mg every 12 hours
|
|||||||||||||||||||||||||||
Arm title
|
Placebo | |||||||||||||||||||||||||||
Arm description |
Subjects were randomised to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5. | |||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet, Capsule
|
|||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||
Dosage and administration details |
Placebo every 12 hours
|
|||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nirmatrelvir 300 milligram (mg) + Ritonavir 100 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects were randomised to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects were randomised to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Nirmatrelvir 300 milligram (mg) + Ritonavir 100 mg
|
||
Reporting group description |
Subjects were randomised to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5 | ||
Reporting group title |
Placebo
|
||
Reporting group description |
Subjects were randomised to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5. |
|
|||||||||||||
End point title |
Time to Sustained Alleviation of Overall COVID-19 Signs and Symptoms Through Day 28 | ||||||||||||
End point description |
Sustained alleviation of targeted COVID-19 signs/symptoms was defined as the event occurring on the first 4 consecutive days when all symptoms scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. Missing severity at baseline was considered as mild. Time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28, was calculated as time (days) from start of study intervention or placebo (Day 1) until sustained alleviation of all targeted COVID-19 associated signs and symptoms. In this end point, time to sustained alleviation is reported consolidated for overall COVID-19 signs and symptoms. mITT1 population included all subjects randomly assigned to study intervention, who received at least 1 dose of study intervention. Subjects were analysed according to the study intervention they were randomised.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
From Day 1 to Day 28
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Nirmatrelvir 300 mg + Ritonavir 100 mg, Placebo | ||||||||||||
Comparison groups |
Nirmatrelvir 300 milligram (mg) + Ritonavir 100 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
1288
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
= 0.6027 | ||||||||||||
Method |
Logrank | ||||||||||||
Confidence interval |
|
||||||||||||||||||||||
End point title |
Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious AEs and AEs Leading to Study and Study Drug Discontinuation | |||||||||||||||||||||
End point description |
AE=any untoward medical occurrence in a subject or clinical study subject temporally associated with use of study intervention, whether or not considered related to study intervention.SAE=any untoward medical occurrence at any dose that resulted in any of following outcomes: death; life-threatening; required inpatient hospitalisation or prolongation of existing hospitalisation; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event. TEAEs=events started on or after study medication start date and time. AEs included serious and non-serious adverse events. AEs that led to study discontinuation and AEs that led to discontinuation of study intervention and then continued study were also reported. Safety analysis set=subjects who received at least 1 dose of study intervention; analyzed according to intervention they actually received. A randomised but not treated subjects was excluded from safety analyses.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
From start of study intervention (Day 1) up to Day 34
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects With COVID-19 Related Hospitalization or Death From any Cause Through Day 28 | ||||||||||||||||||
End point description |
Percentage of subjects with COVID-19 related hospitalisation or death from any cause during the first 28 days of the study was estimated using the Kaplan-Meier (KM) method. mITT1 population included all subjects randomly assigned to study intervention, who received at least 1 dose of study intervention. Subjects were analysed according to the study intervention they were randomised.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
From Day 1 to Day 28
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
Nirmatrelvir 300 mg + Ritonavir 100 mg, Placebo | ||||||||||||||||||
Comparison groups |
Nirmatrelvir 300 milligram (mg) + Ritonavir 100 mg v Placebo
|
||||||||||||||||||
Number of subjects included in analysis |
1288
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
|||||||||||||||||||
P-value |
= 0.1796 [1] | ||||||||||||||||||
Method |
Normal approximation | ||||||||||||||||||
Confidence interval |
|||||||||||||||||||
Notes [1] - P-value reported for COVID-19 hospitalization and death due to any cause. |
|
|||||||||||||
End point title |
Percentage of Subjects With Death Through Week 24 | ||||||||||||
End point description |
Percentage of subjects with death (all-cause) event were reported in this end point. mITT1 population included all subjects randomly assigned to study intervention, who received at least 1 dose of study intervention. Subjects were analysed according to the study intervention they were randomised.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From Day 1 to Week 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of COVID-19 Related Medical Visits per Day Through Day 28 | ||||||||||||
End point description |
Number of COVID-19 related medical visits per day were reported in this endpoint. mITT1 population included all subjects randomly assigned to study intervention, who received at least 1 dose of study intervention. Subjects were analysed according to the study intervention they were randomised.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From Day 1 to Day 28
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Nirmatrelvir 300 mg + Ritonavir 100 mg, Placebo | ||||||||||||
Comparison groups |
Nirmatrelvir 300 milligram (mg) + Ritonavir 100 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
1288
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
= 0.0971 | ||||||||||||
Method |
Negative binomial | ||||||||||||
Confidence interval |
|
|||||||||||||||||||
End point title |
Duration of Hospitalisation and Intensive Care Unit (ICU) Stay Through Day 28 | ||||||||||||||||||
End point description |
mITT1 population included all subjects randomly assigned to study intervention, who received at least 1 dose of study intervention. Subjects were analysed according to the study intervention they were randomised.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
From Day 1 to Day 28
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With Severe Signs and Symptoms of COVID-19 Through Day 28 | ||||||||||||
End point description |
Subjects recorded a daily severity rating of their symptom severity over past 24 hours based on a 4-point scale in which 0 was reported if no symptoms were present; 1 if mild; 2 if moderate; and 3 if severe. A subject with severe score for any targeted symptoms post-baseline was counted as severe. Vomiting and diarrhea each was rated on a 4-point frequency scale where 0 was reported for no occurrence, 1 for 1 to 2 times, 2 for 3 to 4 times, and 3 for 5 or greater. Sense of smell and sense of taste each be rated on a 3-point Likert scale where 0 was reported if the sense of smell/taste was the same as usual, 1 if the sense of smell/taste was less than usual, and 2 for no sense of smell/taste. mITT1 population included all subjects randomly assigned to study intervention, who received at least 1 dose of study intervention. Subjects were analysed according to the study intervention they were randomised. Here, ‘Number of Subjects Analysed’ signifies subjects evaluable for this end point.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From Day 1 to Day 28
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Nirmatrelvir 300 mg + Ritonavir 100 mg, Placebo | ||||||||||||
Statistical analysis description |
Main effects of treatment, geographic region, baseline SARS-CoV-2 serology status and baseline viral load (< 4 log10 copies/mL, >= 4 log10 copies/mL).
|
||||||||||||
Comparison groups |
Nirmatrelvir 300 milligram (mg) + Ritonavir 100 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
1281
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
= 0.1622 | ||||||||||||
Method |
Regression, Logistic | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
0.819
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.618 | ||||||||||||
upper limit |
1.084 |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Time to Sustained Resolution of Each COVID-19 Signs and Symptoms Through Day 28 | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
Sustained resolution was defined as when targeted symptoms are scored as absent for 4 consecutive days. The first day of the 4 consecutive-day period was considered the first event date. In this endpoint time to sustained alleviation is reported for each COVID-19 signs and symptoms. mITT1 population included all subjects randomly assigned to study intervention, who received at least 1 dose of study intervention. Subjects were analysed according to the study intervention they were randomised. Here ''Number of Subjects Analysed''=subjects evaluable for this end point and ''number analysed''= subjects evaluable at specified time points.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
From Day 1 to Day 28
|
|||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Time to Sustained Resolution of Overall COVID-19 Signs and Symptoms Through Day 28 | ||||||||||||
End point description |
Sustained resolution was defined as when targeted symptoms are scored as absent for 4 consecutive days. The first day of the 4 consecutive-day period was considered the first event date. mITT1 population included all subjects randomly assigned to study intervention, who received at least 1 dose of study intervention. Subjects were analysed according to the study intervention they were randomised. Here, ''Number of Subjects Analysed'' signifies subjects evaluable for this endpoint.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From Day 1 to Day 28
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Nirmatrelvir 300 mg + Ritonavir 100 mg, Placebo | ||||||||||||
Comparison groups |
Nirmatrelvir 300 milligram (mg) + Ritonavir 100 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
853
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
= 0.4298 | ||||||||||||
Method |
Logrank | ||||||||||||
Confidence interval |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Time to Sustained Alleviation of Each COVID-19 Signs and Symptoms Through Day 28 | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
Sustained alleviation of targeted COVID-19 signs/symptoms = event occurring on first 4 consecutive days when all symptoms scored as moderate or severe at time of enrollment were scored as mild or absent and those scored mild or absent at time of enrollment were scored absent. Missing severity at baseline was treated as mild.Time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28, was calculated as time (days) from start of study intervention or placebo(Day 1)until sustained alleviation of all targeted COVID-19 associated signs and symptoms. In this endpoint time to sustained resolution is reported consolidated for each COVID-19 signs and symptoms. mITT1 population analysed. 99999=due to variability of data, number of subjects with events available was not sufficient for calculation of limits using Kaplan-Meier method. Subjects analysed according to study intervention they were randomised.''Number of Subjects Analysed''=subjects evaluable for endpoint.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
From Day 1 to Day 28
|
|||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects With Progression to Worsening Status of COVID-19 Signs and Symptoms | ||||||||||||
End point description |
Subjects recorded a daily severity rating of their symptom severity over the past 24 hours based on a 4-point scale in which 0 was reported if no symptoms were present; 1 if mild; 2 if moderate; and 3 if severe. Vomiting and diarrhea was rated on a 4-point frequency scale where 0 is reported for no occurrence, 1 (mild) for 1 to 2 times, 2 (moderate) for 3 to 4 times, and 3 (severe) for 5 or greater. Progression to a worsening status for any targeted symptom was based up on increasing severity (i.e. the first time any targeted symptoms worsened after treatment relative to baseline). mITT1 population included all subjects randomly assigned to study intervention, who received at least 1 dose of study intervention. Subjects were analysed according to the study intervention they were randomised.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From Day 1 to Day 28
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Nirmatrelvir 300 mg + Ritonavir 100 mg, Placebo | ||||||||||||
Statistical analysis description |
Main effects of treatment, geographic region, symptom onset duration (<=3, >3), baseline SARS-CoV-2 serology status (positive/negative), vaccination status (complete/not vaccinated) and baseline viral load (<4 log10 copies/mL, >=4 log10 copies/mL).
|
||||||||||||
Comparison groups |
Nirmatrelvir 300 milligram (mg) + Ritonavir 100 mg v Placebo
|
||||||||||||
Number of subjects included in analysis |
1281
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
= 0.1086 | ||||||||||||
Method |
Regression, Logistic | ||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||
Point estimate |
0.802
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.613 | ||||||||||||
upper limit |
1.05 |
|
|||||||||||||
End point title |
Plasma Concentration Versus Time Summary of PF-07321332 [2] | ||||||||||||
End point description |
Safety analysis set included all subjects who received at least 1 dose of study intervention. Subjects were analyzed according to the intervention they actually received. A randomised but not treated subjects was excluded from the safety analyses. Here ' Number of Subjects Analysed'=subjects evaluable for this end point and 'number analysed'= subjects evaluable at specified time points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1: 1 hour post dose; Day 5: 0 minutes pre-dose
|
||||||||||||
Notes [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Only descriptive analysis was planned for this endpoint. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects With Resting Peripheral Oxygen Saturation Greater Than or Equal to (>=) 95% at Day 1 and Day 5 | ||||||||||||||||||
End point description |
Percentage of subjects with a resting peripheral oxygen saturation >=95% were reported in this endpoint.mITT1 population included all subjects randomly assigned to study intervention, who received at least 1 dose of study intervention. Subjects were analysed according to the study intervention they were randomised.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Day 1 and Day 5
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
Nirmatrelvir 300 mg + Ritonavir 100 mg, Placebo | ||||||||||||||||||
Comparison groups |
Nirmatrelvir 300 milligram (mg) + Ritonavir 100 mg v Placebo
|
||||||||||||||||||
Number of subjects included in analysis |
1242
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
|||||||||||||||||||
P-value |
= 0.3262 | ||||||||||||||||||
Method |
Breslow-Day Test | ||||||||||||||||||
Parameter type |
Odds ratio (OR) | ||||||||||||||||||
Point estimate |
50.333
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
13.163 | ||||||||||||||||||
upper limit |
192.472 |
|
|||||||||||||||||||||||||
End point title |
Change From Baseline in Logarithm to Base10 (Log10) Transformed Viral Load at Days 3, 5, 10 and 14 | ||||||||||||||||||||||||
End point description |
Nasal samples were collected to estimate the viral load in subjects in terms of logarithm to base 10 (log10) copies per milliliter. mITT1 population included all subjects randomly assigned to study intervention, who received at least 1 dose of study intervention. Subjects were analysed according to the study intervention they were randomised. Here, ''Number of Subjects Analysed'' signifies subjects evaluable for this endpoint.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Baseline, Days 3, 5, 10 and 14
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
SAEs and Non-SAEs: From Day 1 to Week 24; All-cause mortality: till Week 24
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Same event may appear as both SAE and non-SAE but are distinct events. An event may be categorised as serious in 1 subject and non-serious in another, or a subject may have experienced both SAE and non-SAE. Safety population comprised of all subjects who received at least 1 dose of study intervention during the study.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
25.0
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects were randomised to receive placebo matched to nirmatrelvir/ritonavir every 12 hours for 10 doses from Day 1 through Day 5. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Nirmatrelvir 300 mg + Ritonavir 100 mg
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects were randomised to receive nirmatrelvir 300 mg and ritonavir 100 mg orally every 12 hours from Day 1 to 5. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
02 Jul 2021 |
Amendment 1: Changed endpoint to include, instead of exclude hospitalisation: Number of COVID-19 related medical visits including hospitalisation through Day 28. Confirmed SARS-CoV-2 infection requirement updated from 72 hours to 5 days. |
||
19 Jul 2021 |
Amendment 2: Vaccination criteria was updated from partially to fully vaccinated and the risk factor of =60 years of age was added. |
||
03 Aug 2021 |
Amendment 3: Vaccination criteria was updated to clarify that subjects without underlying medical conditions associated with an increased risk of developing severe illness from COVID-19 are not eligible if they have been vaccinated. It is only fully vaccinated subjects with underlying medical conditions that are eligible. Primary estimand changed to specify inclusion of participants who were randomised <=3 days after symptom onset. |
||
23 Nov 2021 |
Amendment 4: Secondary endpoints and estimands updated to reflect new hypothesis testing hierarchy. Language was added to provide additional information about the study unblinding plan. |
||
21 Jan 2022 |
Amendment 5: The secondary endpoint of incidence of COVID-19-associated hospitalisations or death from any cause will be analyzed to provide a point estimate and 95% CI to measure associated variability. Other clinically relevant secondary endpoints (COVID-19 related medical visits) will also be analysed. Extend study enrollment to assess potential benefit to subjects at low risk of progression to severe COVID-19 in the clinically relevant endpoint of hospitalisation or death. |
||
09 Jun 2022 |
Amendment 6: Added hypertension as a potential risk and removed hemodynamic and inflammatory effects, and TSH and T4 (free) elevations as potential risks. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
In subject disposition, there was discontinuations due to AE, which was captured under "Death" as reason for discontinuation. Adverse event was COVID-19 pneumonia and the subject died due to that event and discontinued study. |